Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01512797 · ClinicalTrials.gov registry record · NA
Treatment of Diabetes After Gastric Bypass With Sitagliptin
A NA study, sponsored by Blandine Laferrere.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT01512797 is a NA study that has completed, run by Blandine Laferrere. The registered enrollment target is 37 participants.
The verdict
NCT01512797, a NA study, has completed, sponsored by Blandine Laferrere.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
Interventions
- OTHER Placebo
- DRUG Sitagliptin phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01512797
The ClinicalTrials.gov registry entry for NCT01512797 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blandine Laferrere, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01512797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01512797 about?
NCT01512797 is a clinical study titled "Treatment of Diabetes After Gastric Bypass With Sitagliptin". The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
What is the current status of trial NCT01512797?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2012-07. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01512797?
The interventions under investigation include: Placebo (OTHER), Sitagliptin phosphate (DRUG).
Who is sponsoring clinical trial NCT01512797?
This trial is sponsored by Blandine Laferrere, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.